HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
60:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
table 4. GlP1 agonists:@0.519887:0.088780:0.681358:0.088780:0.681358:0.072281:0.519887:0.072281:0.006350:0.009979:0.009979:0.003629:0.009676:0.004233:0.008467:0.004233:0.004233:0.012700:0.006652:0.008467:0.008467:0.004233:0.009979:0.009979:0.009676:0.009071:0.003629:0.006652:0.004536:0.006652
Generic:@0.524927:0.107628:0.577608:0.107628:0.577608:0.092963:0.524927:0.092963:0.011289:0.008601:0.008063:0.008601:0.004301:0.003225:0.008601
trade name:@0.659291:0.107628:0.737507:0.107628:0.737507:0.092963:0.659291:0.092963:0.005644:0.004301:0.008870:0.008870:0.008601:0.003763:0.008063:0.008870:0.012633:0.008601
trial:@0.793656:0.107628:0.818921:0.107628:0.818921:0.092963:0.793656:0.092963:0.005644:0.004301:0.003225:0.008870:0.003225
Lixisenatide:@0.524940:0.123022:0.599487:0.123022:0.599487:0.108993:0.524940:0.108993:0.006209:0.002688:0.006451:0.002688:0.005214:0.008735:0.008198:0.009179:0.004556:0.002688:0.009206:0.008735
Adlyxin™:@0.659305:0.123022:0.719122:0.123022:0.719122:0.108993:0.659305:0.108993:0.009945:0.009206:0.002688:0.007203:0.006451:0.002688:0.008198:0.013439
ELIXA:@0.793669:0.123022:0.828248:0.123022:0.828248:0.108993:0.793669:0.108993:0.007203:0.006209:0.003037:0.008184:0.009945
Liraglutide:@0.524954:0.138416:0.592163:0.138416:0.592163:0.124387:0.524954:0.124387:0.006209:0.002688:0.004045:0.009179:0.009045:0.002688:0.008171:0.004556:0.002688:0.009206:0.008735
Victoza:@0.659318:0.138416:0.708385:0.138416:0.708385:0.124387:0.659318:0.124387:0.009434:0.002688:0.008695:0.004556:0.008803:0.005712:0.009179
LEADER:@0.793683:0.138416:0.842400:0.138416:0.842400:0.124387:0.793683:0.124387:0.006209:0.007203:0.009945:0.009999:0.007203:0.008158
semaglutide:@0.524967:0.153810:0.607268:0.153810:0.607268:0.139781:0.524967:0.139781:0.006693:0.008735:0.012606:0.009179:0.009045:0.002688:0.008171:0.004556:0.002688:0.009206:0.008735
Ozempic:@0.659332:0.153810:0.718612:0.153810:0.718612:0.139781:0.659332:0.139781:0.011679:0.005712:0.008735:0.012606:0.009165:0.002688:0.008695
sUsTAIN-6:@0.793696:0.153810:0.856444:0.153810:0.856444:0.139781:0.793696:0.139781:0.006693:0.008803:0.006693:0.005725:0.009945:0.003037:0.009945:0.004462:0.007445
Exenatide:@0.524981:0.169204:0.589932:0.169204:0.589932:0.155175:0.524981:0.155175:0.007203:0.006451:0.008735:0.008198:0.009179:0.004556:0.002688:0.009206:0.008735
Bydureon/Byetta:@0.659345:0.169204:0.769237:0.169204:0.769237:0.155175:0.659345:0.155175:0.007714:0.007203:0.009206:0.008171:0.004045:0.008735:0.008803:0.008198:0.005873:0.007714:0.007203:0.008735:0.004556:0.004556:0.009179
EXsCEL:@0.793710:0.169204:0.840128:0.169204:0.840128:0.155175:0.793710:0.155175:0.007203:0.008184:0.006693:0.010926:0.007203:0.006209
Dulaglutide:@0.524994:0.184598:0.600119:0.184598:0.600119:0.170569:0.524994:0.170569:0.009999:0.008171:0.002688:0.009179:0.009045:0.002688:0.008171:0.004556:0.002688:0.009206:0.008735
Trulicity:@0.659359:0.184598:0.705818:0.184598:0.705818:0.170569:0.659359:0.170569:0.005725:0.004045:0.008171:0.002688:0.002688:0.008695:0.002688:0.004556:0.007203
REWIND:@0.793723:0.184598:0.844967:0.184598:0.844967:0.170569:0.793723:0.170569:0.008158:0.007203:0.012902:0.003037:0.009945:0.009999
Albiglutide:@0.525007:0.199992:0.594582:0.199992:0.594582:0.185963:0.525007:0.185963:0.009945:0.002688:0.009165:0.002688:0.009045:0.002688:0.008171:0.004556:0.002688:0.009206:0.008735
Tanzeum:@0.659372:0.199992:0.717698:0.199992:0.717698:0.185963:0.659372:0.185963:0.005725:0.009179:0.008198:0.005712:0.008735:0.008171:0.012606
HARMONY:@0.793737:0.199992:0.862948:0.199992:0.862948:0.185963:0.793737:0.185963:0.009179:0.009945:0.008158:0.012351:0.011679:0.009945:0.007956
semaglutide pO:@0.525021:0.217952:0.630679:0.217952:0.630679:0.203923:0.525021:0.203923:0.006693:0.008735:0.012606:0.009179:0.009045:0.002688:0.008171:0.004556:0.002688:0.009206:0.008735:0.003723:0.007956:0.011679
pIONEER 6:@0.793737:0.217952:0.860086:0.217952:0.860086:0.203923:0.793737:0.203923:0.007956:0.003037:0.011679:0.009945:0.007203:0.007203:0.008158:0.003723:0.007445
mechanism of action:@0.519047:0.246100:0.690732:0.246100:0.690732:0.227768:0.519047:0.227768:0.015119:0.010751:0.010751:0.010079:0.011087:0.010079:0.004032:0.007392:0.015791:0.004704:0.010751:0.004704:0.004704:0.011087:0.010751:0.005040:0.004032:0.010751:0.010079
All the drugs in this class work in the same way (see Figure 6).:@0.519047:0.259597:0.923739:0.259597:0.923739:0.243815:0.519047:0.243815:0.010735:0.002570:0.002570:0.003069:0.004672:0.008769:0.009374:0.003069:0.009903:0.004097:0.008739:0.009722:0.005413:0.003069:0.002570:0.008769:0.003069:0.004672:0.008769:0.002570:0.005413:0.003069:0.009328:0.002570:0.009873:0.005413:0.005413:0.003069:0.012110:0.009449:0.004097:0.007136:0.003069:0.002570:0.008769:0.003069:0.004672:0.008769:0.009374:0.003069:0.005413:0.009873:0.013728:0.009374:0.003069:0.012110:0.009873:0.007650:0.003069:0.005125:0.005413:0.009374:0.009374:0.003069:0.006879:0.002570:0.009722:0.008739:0.004097:0.009374:0.003069:0.007922:0.005125:0.004188
The additional direct subcutaneous injection of GLp-1 RA :@0.519047:0.273487:0.928017:0.273487:0.928017:0.257704:0.519047:0.257704:0.006138:0.008920:0.009525:0.004702:0.010024:0.010054:0.010054:0.002721:0.004823:0.002721:0.009601:0.008920:0.010024:0.002721:0.004702:0.010054:0.002721:0.004248:0.009525:0.009480:0.004823:0.004702:0.005564:0.008890:0.010009:0.009480:0.008890:0.004823:0.010024:0.008920:0.009525:0.009601:0.008890:0.005564:0.004702:0.002721:0.008920:0.002767:0.009525:0.009480:0.004823:0.002721:0.009601:0.008920:0.004702:0.009601:0.004445:0.004702:0.012881:0.006683:0.008648:0.004717:0.008074:0.004702:0.008875:0.011188:0.004188
further augments the action of GLp-1 in the body, thereby :@0.519047:0.287376:0.928063:0.287376:0.928063:0.271593:0.519047:0.271593:0.004445:0.008890:0.004248:0.004823:0.008920:0.009525:0.004248:0.003659:0.010024:0.008890:0.009873:0.013879:0.009525:0.008920:0.004823:0.005564:0.003659:0.004823:0.008920:0.009525:0.003659:0.010024:0.009480:0.004823:0.002721:0.009601:0.008920:0.003659:0.009601:0.004445:0.003659:0.012881:0.006683:0.008648:0.004717:0.008074:0.003659:0.002721:0.008920:0.003659:0.004823:0.008920:0.009525:0.003659:0.010009:0.009601:0.010054:0.007801:0.003886:0.003659:0.004823:0.008920:0.009525:0.004248:0.009525:0.010009:0.008104:0.004188
enhancing its physiological effects. The drug stimulates :@0.519047:0.301265:0.928032:0.301265:0.928032:0.285482:0.519047:0.285482:0.009525:0.008920:0.008920:0.010024:0.008920:0.009480:0.002721:0.008920:0.009873:0.007408:0.002721:0.004823:0.005564:0.007408:0.010009:0.008920:0.007801:0.005564:0.002721:0.009601:0.002721:0.009601:0.009873:0.002721:0.009480:0.010024:0.002721:0.007408:0.009525:0.004445:0.004445:0.009525:0.009480:0.004823:0.005564:0.003886:0.007408:0.006138:0.008920:0.009525:0.007408:0.010054:0.004248:0.008890:0.009873:0.007408:0.005564:0.004823:0.002721:0.013879:0.008890:0.002721:0.010024:0.004823:0.009525:0.005866:0.004188
glucose-dependent insulin secretion from the beta cell of :@0.519047:0.315154:0.927972:0.315154:0.927972:0.299371:0.519047:0.299371:0.009873:0.002721:0.008890:0.009480:0.009601:0.005564:0.009525:0.004717:0.010054:0.009525:0.010009:0.009525:0.008920:0.010054:0.009525:0.008920:0.004823:0.004218:0.002721:0.008920:0.005564:0.008890:0.002721:0.002721:0.008920:0.004218:0.005564:0.009525:0.009480:0.004248:0.009525:0.004823:0.002721:0.009601:0.008920:0.004218:0.004445:0.004248:0.009601:0.013879:0.004218:0.004823:0.008920:0.009525:0.004218:0.010009:0.009525:0.004823:0.010024:0.004218:0.009480:0.009525:0.002721:0.002721:0.004218:0.009601:0.004747:0.004188
the pancreas; it suppresses glucose-dependent glucagon :@0.519047:0.329043:0.928002:0.329043:0.928002:0.313261:0.519047:0.313261:0.004823:0.008920:0.009525:0.003281:0.010009:0.010024:0.008920:0.009480:0.004248:0.009525:0.010024:0.005564:0.003886:0.003281:0.002721:0.004823:0.003281:0.005564:0.008890:0.010009:0.010009:0.004248:0.009525:0.005564:0.005564:0.009525:0.005564:0.003281:0.009873:0.002721:0.008890:0.009480:0.009601:0.005564:0.009525:0.004717:0.010054:0.009525:0.010009:0.009525:0.008920:0.010054:0.009525:0.008920:0.004823:0.003281:0.009873:0.002721:0.008890:0.009480:0.010024:0.009873:0.009601:0.009223:0.004188
secretion by inhibiting the alpha cells of the pancreas, re-:@0.519047:0.342932:0.923799:0.342932:0.923799:0.327150:0.519047:0.327150:0.005564:0.009525:0.009480:0.004248:0.009525:0.004823:0.002721:0.009601:0.008920:0.004158:0.010009:0.007801:0.004158:0.002721:0.008920:0.008920:0.002721:0.010009:0.002721:0.004823:0.002721:0.008920:0.009873:0.004158:0.004823:0.008920:0.009525:0.004158:0.010024:0.002721:0.010009:0.008920:0.010024:0.004158:0.009480:0.009525:0.002721:0.002721:0.005564:0.004158:0.009601:0.004445:0.004158:0.004823:0.008920:0.009525:0.004158:0.010009:0.010024:0.008920:0.009480:0.004248:0.009525:0.010024:0.005564:0.003886:0.004158:0.004248:0.009525:0.005020
ducing hepatic glucose production; it has an effect on :@0.519047:0.356822:0.927972:0.356822:0.927972:0.341039:0.519047:0.341039:0.010054:0.008890:0.009480:0.002721:0.008920:0.009873:0.006169:0.008920:0.009525:0.010009:0.010024:0.004823:0.002721:0.009480:0.006169:0.009873:0.002721:0.008890:0.009480:0.009601:0.005564:0.009525:0.006169:0.010009:0.004248:0.009601:0.010054:0.008890:0.009480:0.004823:0.002721:0.009601:0.008920:0.003886:0.006169:0.002721:0.004823:0.006169:0.008920:0.010024:0.005564:0.006169:0.010024:0.008920:0.006169:0.009525:0.004445:0.004445:0.009525:0.009480:0.004823:0.006169:0.009601:0.009223:0.004188
the gastro-intestinal tract, producing a feeling of fullness; :@0.519047:0.370711:0.928047:0.370711:0.928047:0.354928:0.519047:0.354928:0.004823:0.008920:0.009525:0.005216:0.009873:0.010024:0.005564:0.004823:0.004248:0.009601:0.004717:0.002721:0.008920:0.004823:0.009525:0.005564:0.004823:0.002721:0.008920:0.010024:0.002721:0.005216:0.004823:0.004248:0.010024:0.009480:0.004823:0.003886:0.005216:0.010009:0.004248:0.009601:0.010054:0.008890:0.009480:0.002721:0.008920:0.009873:0.005216:0.010024:0.005216:0.004445:0.009525:0.009525:0.002721:0.002721:0.008920:0.009873:0.005216:0.009601:0.004445:0.005216:0.004445:0.008890:0.002721:0.002721:0.008920:0.009525:0.005564:0.005564:0.004188:0.004188
and has a direct effect on the CNs, enhancing satiety. It :@0.519047:0.384600:0.927972:0.384600:0.927972:0.368817:0.519047:0.368817:0.010024:0.008920:0.010054:0.004762:0.008920:0.010024:0.005564:0.004762:0.010024:0.004762:0.010054:0.002721:0.004248:0.009525:0.009480:0.004823:0.004762:0.009525:0.004445:0.004445:0.009525:0.009480:0.004823:0.004762:0.009601:0.008920:0.004762:0.004823:0.008920:0.009525:0.004762:0.011989:0.010886:0.007227:0.003886:0.004762:0.009525:0.008920:0.008920:0.010024:0.008920:0.009480:0.002721:0.008920:0.009873:0.004762:0.005564:0.010024:0.004823:0.002721:0.009525:0.004823:0.007801:0.003886:0.004762:0.003115:0.005125:0.004188
thus suppresses appetite and facilitates weight loss.:@0.519047:0.398489:0.878109:0.398489:0.878109:0.382706:0.519047:0.382706:0.004823:0.008920:0.008890:0.005564:0.003886:0.005564:0.008890:0.010009:0.010009:0.004248:0.009525:0.005564:0.005564:0.009525:0.005564:0.003886:0.010024:0.010009:0.010009:0.009525:0.004823:0.002721:0.004823:0.009525:0.003886:0.010024:0.008920:0.010054:0.003886:0.004445:0.010024:0.009480:0.002721:0.002721:0.002721:0.004823:0.010024:0.004823:0.009525:0.005564:0.003886:0.012262:0.009525:0.002721:0.009873:0.008920:0.004823:0.003886:0.002721:0.009601:0.005564:0.005564:0.004188
Food:@0.522456:0.477331:0.547528:0.477331:0.547528:0.465281:0.522456:0.465281:0.005507:0.006457:0.006457:0.006652
Secretes:@0.621691:0.457836:0.663261:0.457836:0.663261:0.445786:0.621691:0.445786:0.006010:0.005907:0.005140:0.003973:0.005907:0.003950:0.005907:0.004774
GLP-1 in:@0.621932:0.466287:0.663020:0.466287:0.663020:0.454237:0.621932:0.454237:0.007625:0.005644:0.006228:0.003606:0.006136:0.002370:0.002931:0.006549
response:@0.619951:0.474737:0.664990:0.474737:0.664990:0.462687:0.619951:0.462687:0.003973:0.005907:0.004774:0.006697:0.006457:0.006549:0.004774:0.005907
to food:@0.624530:0.483188:0.660399:0.483188:0.660399:0.471138:0.624530:0.471138:0.003950:0.006457:0.002370:0.003526:0.006457:0.006457:0.006652
Slows:@0.698751:0.514555:0.727177:0.514555:0.727177:0.502505:0.698751:0.502505:0.005907:0.002942:0.006365:0.008438:0.004774
gastric:@0.696312:0.524416:0.729627:0.524416:0.729627:0.512366:0.696312:0.512366:0.006560:0.005816:0.004774:0.004018:0.004076:0.002931:0.005140
emptying:@0.688882:0.534277:0.737058:0.534277:0.737058:0.522227:0.688882:0.522227:0.005907:0.009708:0.006697:0.004099:0.005724:0.002931:0.006549:0.006560
Suppresses:@0.804375:0.524101:0.860335:0.524101:0.860335:0.512051:0.804375:0.512051:0.005942:0.006514:0.006697:0.006697:0.003973:0.005907:0.004774:0.004774:0.005907:0.004774
glucagon:@0.809091:0.533961:0.855629:0.533961:0.855629:0.521911:0.809091:0.521911:0.006560:0.002942:0.006514:0.005140:0.005816:0.006560:0.006457:0.006549
secretion:@0.809526:0.543822:0.855183:0.543822:0.855183:0.531772:0.809526:0.531772:0.004774:0.005907:0.005140:0.003973:0.005907:0.004018:0.002931:0.006457:0.006549
Stimulates:@0.806905:0.451199:0.859293:0.451199:0.859293:0.439149:0.806905:0.439149:0.005896:0.004018:0.002931:0.009708:0.006514:0.002942:0.005747:0.003950:0.005907:0.004774
insulin:@0.816510:0.461060:0.849699:0.461060:0.849699:0.449010:0.816510:0.449010:0.002931:0.006549:0.004774:0.006514:0.002942:0.002931:0.006549
secretion:@0.810282:0.470921:0.855938:0.470921:0.855938:0.458871:0.810282:0.458871:0.004774:0.005907:0.005140:0.003973:0.005907:0.004018:0.002931:0.006457:0.006549
Decreases:@0.685219:0.466799:0.735237:0.466799:0.735237:0.454749:0.685219:0.454749:0.007819:0.005907:0.005140:0.003973:0.005907:0.005816:0.004774:0.005907:0.004774
appetite:@0.689260:0.476660:0.731185:0.476660:0.731185:0.464610:0.689260:0.464610:0.005816:0.006697:0.006697:0.005907:0.004018:0.002931:0.003950:0.005907
GLP-1:@0.664291:0.496283:0.693530:0.496283:0.693530:0.484233:0.664291:0.484233:0.007625:0.005644:0.006228:0.003606:0.006136
Pancreas:@0.758512:0.511045:0.802646:0.511045:0.802646:0.498995:0.758512:0.498995:0.006159:0.005816:0.006549:0.005140:0.003973:0.005907:0.005816:0.004774
Stomach:@0.736107:0.571837:0.779623:0.571837:0.779623:0.559787:0.736107:0.559787:0.005896:0.003950:0.006457:0.009708:0.005816:0.005140:0.006549
Glucagon:@0.873592:0.516320:0.921229:0.516320:0.921229:0.504270:0.873592:0.504270:0.007659:0.002942:0.006514:0.005140:0.005816:0.006560:0.006457:0.006549
Insulin:@0.877839:0.467894:0.911189:0.467894:0.911189:0.455844:0.877839:0.455844:0.003091:0.006549:0.004774:0.006514:0.002942:0.002931:0.006549
Small :@0.584324:0.520492:0.614044:0.520492:0.614044:0.508442:0.584324:0.508442:0.005942:0.009708:0.005816:0.002942:0.002942:0.002370
intestine:@0.576275:0.528942:0.619734:0.528942:0.619734:0.516892:0.576275:0.516892:0.002931:0.006491:0.003950:0.005907:0.004774:0.004018:0.002931:0.006549:0.005907
X:@0.824949:0.513500:0.836209:0.516099:0.842416:0.496146:0.831156:0.493547:-0.165140
Brain:@0.744934:0.453309:0.770796:0.453309:0.770796:0.441259:0.744934:0.441259:0.006594:0.003973:0.005816:0.002931:0.006549
figure 6. mechanism of action of GlP-1 rAs:@0.519047:0.586481:0.835035:0.586481:0.835035:0.569982:0.519047:0.569982:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.004233:0.008467:0.004233:0.004233:0.013607:0.009676:0.009676:0.009071:0.009979:0.009071:0.003629:0.006652:0.014212:0.004233:0.009676:0.004233:0.004233:0.009979:0.009676:0.004536:0.003629:0.009676:0.009071:0.004233:0.009676:0.004233:0.004233:0.012700:0.006652:0.008467:0.006350:0.008467:0.004233:0.008769:0.011188:0.006652
randomised controlled studies (see table 5):@0.519047:0.614877:0.877872:0.614877:0.877872:0.596545:0.519047:0.596545:0.009743:0.011087:0.010079:0.011087:0.010751:0.015791:0.004032:0.007392:0.010751:0.011087:0.004704:0.010751:0.010751:0.010079:0.005040:0.005376:0.010751:0.004032:0.004032:0.010751:0.011087:0.004704:0.007392:0.005040:0.010079:0.011087:0.004032:0.010751:0.007392:0.004704:0.006384:0.007392:0.010751:0.010751:0.004704:0.007056:0.011087:0.011087:0.004032:0.010751:0.004704:0.009407:0.006384
Lixisenatide :@0.519047:0.630939:0.607101:0.630939:0.607101:0.615157:0.519047:0.615157:0.006985:0.003024:0.007257:0.003024:0.005866:0.009827:0.009223:0.010326:0.005125:0.003024:0.010357:0.009827:0.004188
(elixA study):@0.607932:0.630939:0.704921:0.630939:0.704921:0.614441:0.607932:0.614441:0.005745:0.007862:0.006652:0.004233:0.010281:0.011188:0.005065:0.007862:0.004536:0.009071:0.009979:0.008769:0.005745
 is a short-acting GLp-1 RA re-:@0.704921:0.630939:0.923799:0.630939:0.923799:0.615157:0.704921:0.615157:0.005004:0.003024:0.005866:0.005020:0.010326:0.005004:0.005866:0.009223:0.009903:0.004551:0.005125:0.005020:0.010326:0.009782:0.005125:0.003024:0.009223:0.010175:0.005004:0.013184:0.006985:0.008950:0.005020:0.008376:0.005004:0.009177:0.011188:0.005004:0.004551:0.009827:0.005020
quiring  twice-daily injections.  When  tested  for  primary :@0.519047:0.644829:0.928002:0.644829:0.928002:0.629046:0.519047:0.629046:0.010311:0.009192:0.003024:0.004551:0.003024:0.009223:0.010175:0.004188:0.002646:0.005125:0.012564:0.003024:0.009782:0.009827:0.005020:0.010357:0.010326:0.003024:0.003024:0.008104:0.006849:0.003024:0.009223:0.003069:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.004188:0.002646:0.014514:0.009223:0.009827:0.009223:0.004188:0.002646:0.005125:0.009827:0.005866:0.005125:0.009827:0.010357:0.004188:0.002646:0.004747:0.009903:0.004551:0.004188:0.002661:0.008950:0.004551:0.003024:0.014182:0.010326:0.004551:0.008104:0.004188
MACE in a RCT, (ELIXA), it showed no statistical differ-:@0.519047:0.658718:0.923829:0.658718:0.923829:0.642935:0.519047:0.642935:0.013894:0.011188:0.012292:0.008104:0.006274:0.003024:0.009223:0.006274:0.010326:0.006274:0.009177:0.012292:0.006441:0.004188:0.006274:0.005579:0.008104:0.006985:0.003417:0.009207:0.011188:0.005579:0.004188:0.006274:0.003024:0.005125:0.006274:0.005866:0.009223:0.009903:0.012564:0.009827:0.010357:0.006274:0.009223:0.009903:0.006274:0.005866:0.005125:0.010326:0.005125:0.003024:0.005866:0.005125:0.003024:0.009782:0.010326:0.003024:0.006290:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.005020
ence from standard therapy of care (see Figure 7).:@0.519047:0.672607:0.890673:0.672607:0.890673:0.656824:0.519047:0.656824:0.009827:0.009223:0.009782:0.009827:0.004188:0.004747:0.004551:0.009903:0.014182:0.004188:0.005866:0.005125:0.010326:0.009223:0.010357:0.010326:0.004551:0.010357:0.004188:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.009903:0.004747:0.004188:0.009782:0.010326:0.004551:0.009827:0.004188:0.005579:0.005866:0.009827:0.009827:0.004188:0.007333:0.003024:0.010175:0.009192:0.004551:0.009827:0.004188:0.008376:0.005579:0.004188
15:@0.890630:0.667314:0.900346:0.667314:0.900346:0.658160:0.890630:0.658160:0.004858:0.004858
figure 7. lixisenatide :@0.519047:0.863207:0.674471:0.863207:0.674471:0.846709:0.519047:0.846709:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.004233:0.008467:0.004233:0.004233:0.006652:0.003629:0.008467:0.003629:0.006652:0.009676:0.009071:0.009979:0.004536:0.003629:0.009979:0.009676:0.004233
vs.:@0.674456:0.863207:0.693808:0.863207:0.693808:0.846709:0.674456:0.846709:0.008467:0.006652:0.004233
 placebo primary outcomes:@0.693808:0.863207:0.898520:0.863207:0.898520:0.846709:0.693808:0.846709:0.004233:0.009979:0.003629:0.009979:0.009676:0.009676:0.009979:0.009676:0.004233:0.009979:0.004838:0.003629:0.014212:0.009979:0.004838:0.008769:0.004233:0.009676:0.009071:0.004536:0.009676:0.009676:0.014212:0.009676:0.006652
leADer (liraglutide and Cardiovascular Outcomes in type 2 :@0.533335:0.887741:0.928032:0.887741:0.928032:0.871243:0.533335:0.871243:0.005896:0.007106:0.010432:0.009827:0.007106:0.008013:0.002842:0.004989:0.005896:0.002873:0.004082:0.009223:0.009223:0.002873:0.008315:0.003780:0.002873:0.009223:0.008920:0.002842:0.009223:0.008315:0.009223:0.002842:0.011037:0.009223:0.004082:0.009223:0.002873:0.008920:0.007711:0.009223:0.005896:0.008920:0.008315:0.002873:0.009223:0.004082:0.002842:0.011944:0.008315:0.003780:0.008920:0.008920:0.013456:0.008920:0.005896:0.002842:0.002873:0.008315:0.002842:0.005594:0.008013:0.009223:0.008920:0.002842:0.008467:0.004233
Diabetes).:@0.519047:0.902150:0.586932:0.902150:0.586932:0.885651:0.519047:0.885651:0.009827:0.002873:0.009223:0.009223:0.008920:0.003780:0.008920:0.005896:0.004989:0.004233
16:@0.586175:0.896851:0.595558:0.896851:0.595558:0.887282:0.586175:0.887282:0.004472:0.004911
 The results of liraglutide for both the primary MACE :@0.595120:0.902150:0.927996:0.902150:0.927996:0.886367:0.595120:0.886367:0.003205:0.005685:0.008467:0.009071:0.003205:0.003795:0.009071:0.005110:0.008436:0.002268:0.004369:0.005110:0.003205:0.009147:0.003991:0.003205:0.002268:0.002268:0.003795:0.009570:0.009419:0.002268:0.008436:0.004369:0.002268:0.009601:0.009071:0.003205:0.003991:0.009147:0.003795:0.003205:0.009555:0.009147:0.004369:0.008467:0.003205:0.004369:0.008467:0.009071:0.003205:0.008195:0.003795:0.002268:0.013426:0.009570:0.003795:0.007348:0.003205:0.013138:0.010432:0.011536:0.008104:0.004188
outcomes (13% reduction) and death from cardiovascular :@0.519041:0.916559:0.927996:0.916559:0.927996:0.900776:0.519041:0.900776:0.009147:0.008436:0.004369:0.009026:0.009147:0.013426:0.009071:0.005110:0.006395:0.004823:0.007620:0.007620:0.010961:0.006395:0.003795:0.009071:0.009601:0.008436:0.009026:0.004369:0.002268:0.009147:0.008467:0.004823:0.006395:0.009570:0.008467:0.009601:0.006395:0.009601:0.009071:0.009570:0.004369:0.008467:0.006395:0.003991:0.003795:0.009147:0.013426:0.006395:0.009026:0.009570:0.003795:0.009601:0.002268:0.009147:0.007620:0.009570:0.005110:0.009026:0.008436:0.002268:0.009570:0.004551:0.004188
causes (22% reduction) were both statically significant and :@0.519041:0.930967:0.927966:0.930967:0.927966:0.915185:0.519041:0.915185:0.009026:0.009570:0.008436:0.005110:0.009071:0.005110:0.006138:0.004823:0.007620:0.007620:0.010961:0.006138:0.003795:0.009071:0.009601:0.008436:0.009026:0.004369:0.002268:0.009147:0.008467:0.004823:0.006138:0.011808:0.009071:0.003795:0.009071:0.006138:0.009555:0.009147:0.004369:0.008467:0.006138:0.005110:0.004369:0.009570:0.004369:0.002268:0.009026:0.009570:0.002268:0.002268:0.007348:0.006138:0.005110:0.002268:0.009419:0.008467:0.002268:0.003304:0.003304:0.009026:0.009570:0.008467:0.004369:0.006138:0.009570:0.008467:0.010357:0.004188
showed superiority over standard care (see Figure 8).:@0.519041:0.945376:0.866885:0.945376:0.866885:0.929593:0.519041:0.929593:0.005110:0.008467:0.009147:0.011808:0.009071:0.009601:0.003432:0.005110:0.008436:0.009555:0.009071:0.003795:0.002268:0.009147:0.003795:0.002268:0.004369:0.007348:0.003432:0.009147:0.007620:0.009071:0.003795:0.003432:0.005110:0.004369:0.009570:0.008467:0.009601:0.009570:0.003795:0.009601:0.003432:0.009026:0.009570:0.003795:0.009071:0.003432:0.004823:0.005110:0.009071:0.009071:0.003432:0.006577:0.002268:0.009419:0.008436:0.003795:0.009071:0.003432:0.007620:0.004823:0.004188
CANvAs programme:@0.076190:0.474680:0.231613:0.474680:0.231613:0.458181:0.076190:0.458181:0.011793:0.011188:0.011188:0.010583:0.011188:0.007862:0.004233:0.009979:0.004838:0.009676:0.009979:0.004838:0.009979:0.014212:0.014212:0.009676
The population studied had a high risk of cardiovascular :@0.076190:0.491617:0.485129:0.491617:0.485129:0.475834:0.076190:0.475834:0.006441:0.009223:0.009827:0.003523:0.010311:0.009903:0.010311:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.003523:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.010357:0.003538:0.009223:0.010326:0.010357:0.003523:0.010326:0.003538:0.009223:0.003024:0.010175:0.009223:0.003523:0.004551:0.003024:0.005866:0.007590:0.003538:0.009903:0.004747:0.003523:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188
events receiving standard of care; 81% of patients had :@0.076190:0.505991:0.485129:0.505991:0.485129:0.490208:0.076190:0.490208:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004672:0.004551:0.009827:0.009782:0.009827:0.003024:0.008376:0.003024:0.009223:0.010175:0.004672:0.005866:0.005125:0.010326:0.009223:0.010357:0.010326:0.004551:0.010357:0.004672:0.009903:0.004747:0.004672:0.009782:0.010326:0.004551:0.009827:0.004188:0.004672:0.008376:0.008376:0.011717:0.004687:0.009903:0.004747:0.004672:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004672:0.009223:0.010326:0.010357:0.004188
prior cardiovascular disease or chronic kidney disease.:@0.076190:0.520365:0.475483:0.520365:0.475483:0.504582:0.076190:0.504582:0.010311:0.004551:0.003024:0.009903:0.004551:0.004188:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.009903:0.004551:0.004188:0.009782:0.009223:0.004551:0.009903:0.009223:0.003024:0.009782:0.004188:0.007590:0.003024:0.010357:0.009223:0.009827:0.008104:0.004188:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188
A  potentially  greater  benefit  was  seen  in  those  with :@0.090477:0.534739:0.485114:0.534739:0.485114:0.518956:0.090477:0.518956:0.010886:0.004188:0.003719:0.010009:0.009601:0.004823:0.009525:0.008920:0.004823:0.002721:0.010024:0.002721:0.002721:0.007801:0.004188:0.003719:0.009873:0.004248:0.009525:0.010024:0.004823:0.009525:0.004248:0.004188:0.003719:0.010009:0.009525:0.008920:0.009525:0.003530:0.003530:0.004823:0.004188:0.003719:0.012262:0.010024:0.005564:0.004188:0.003719:0.005564:0.009525:0.009525:0.008920:0.004188:0.003719:0.002721:0.008920:0.004188:0.003719:0.004823:0.008920:0.009601:0.005564:0.009525:0.004188:0.003719:0.012262:0.002721:0.004823:0.009223:0.004188
established cardiovascular disease and subgroups with :@0.076190:0.549113:0.485144:0.549113:0.485144:0.533331:0.076190:0.533331:0.009525:0.005564:0.004823:0.010024:0.010009:0.002721:0.002721:0.005564:0.008920:0.009525:0.010054:0.007302:0.009480:0.010024:0.004248:0.010054:0.002721:0.009601:0.008074:0.010024:0.005564:0.009480:0.008890:0.002721:0.010024:0.004248:0.007302:0.010054:0.002721:0.005564:0.009525:0.010024:0.005564:0.009525:0.007302:0.010024:0.008920:0.010054:0.007302:0.005564:0.008890:0.010009:0.009873:0.004248:0.009601:0.008890:0.010009:0.005564:0.007302:0.012262:0.002721:0.004823:0.009223:0.004188
an eGFR <60 ml/min/1.73 m Canagliflozin significantly re:@0.076190:0.563487:0.476224:0.563442:0.476224:0.547659:0.076190:0.547705:0.010024:0.008920:0.003780:0.009525:0.012881:0.007030:0.008875:0.003780:0.008860:0.008074:0.008074:0.003810:0.013879:0.002721:0.006305:0.013879:0.002721:0.008920:0.006305:0.008074:0.003886:0.008074:0.008074:0.003795:0.014182:0.012654:0.011989:0.010024:0.008920:0.010024:0.009873:0.002721:0.002721:0.003515:0.003515:0.009601:0.006123:0.002721:0.008920:0.003780:0.005564:0.002721:0.009873:0.008920:0.002721:0.003530:0.003530:0.009480:0.010024:0.008920:0.004823:0.002721:0.007801:0.003780:0.004248:0.125954
2   :@0.270329:0.558143:0.283518:0.558143:0.283518:0.548989:0.270329:0.548989:0.004858:0.003710:0.002192:0.002429
.:@0.275014:0.563442:0.279202:0.563442:0.279202:0.547659:0.275014:0.547659:0.004188
-:@0.475922:0.563442:0.480941:0.563442:0.480941:0.547659:0.475922:0.547659:0.005020
duced risk of primary composite cardiovascular outcome :@0.076189:0.577816:0.485129:0.577816:0.485129:0.562033:0.076189:0.562033:0.010054:0.008890:0.009480:0.009525:0.010054:0.003916:0.004248:0.002721:0.005564:0.007287:0.003916:0.009601:0.004445:0.003916:0.010009:0.004248:0.002721:0.013879:0.010024:0.004248:0.007801:0.003916:0.009480:0.009601:0.013879:0.010009:0.009601:0.005564:0.002721:0.004823:0.009525:0.003916:0.009480:0.010024:0.004248:0.010054:0.002721:0.009601:0.008074:0.010024:0.005564:0.009480:0.008890:0.002721:0.010024:0.004248:0.003916:0.009601:0.008890:0.004823:0.009480:0.009601:0.013879:0.009827:0.004188
by 13%   placebo, and all-cause death (15%) and risk of :@0.076189:0.592190:0.485114:0.592190:0.485114:0.576407:0.076189:0.576407:0.010009:0.007801:0.004309:0.008074:0.008074:0.011415:0.004188:0.013789:0.004324:0.010009:0.002721:0.010024:0.009480:0.009525:0.010009:0.009601:0.003886:0.004309:0.010024:0.008920:0.010054:0.004324:0.010024:0.002721:0.002721:0.004717:0.009480:0.010024:0.008890:0.005564:0.009525:0.004324:0.010054:0.009525:0.010024:0.004823:0.008920:0.004309:0.005277:0.008074:0.008074:0.011415:0.005277:0.004324:0.010024:0.008920:0.010054:0.004309:0.004248:0.002721:0.005564:0.007287:0.004309:0.009601:0.004747:0.004188
vs:@0.130210:0.592190:0.144149:0.592190:0.144149:0.576407:0.130210:0.576407:0.008074:0.005866
cardiovascular death (22%). The sodium-glucose cotrans-:@0.076189:0.606564:0.480971:0.606564:0.480971:0.590781:0.076189:0.590781:0.009480:0.010024:0.004248:0.010054:0.002721:0.009601:0.008074:0.010024:0.005564:0.009480:0.008890:0.002721:0.010024:0.004248:0.004188:0.010054:0.009525:0.010024:0.004823:0.008920:0.004188:0.005277:0.008074:0.008074:0.011415:0.005277:0.003886:0.004188:0.006138:0.008920:0.009525:0.004188:0.005564:0.009601:0.010054:0.002721:0.008890:0.013879:0.004717:0.009873:0.002721:0.008890:0.009480:0.009601:0.005564:0.009525:0.004188:0.009480:0.009601:0.004823:0.004248:0.010024:0.008920:0.005564:0.005020
porter 2 (sGLT2) inhibitor :@0.076189:0.620938:0.260596:0.620938:0.260596:0.605156:0.076189:0.605156:0.010009:0.009601:0.004248:0.004823:0.009525:0.004248:0.007817:0.008074:0.007817:0.005277:0.007227:0.012881:0.006683:0.006138:0.008074:0.005277:0.007817:0.002721:0.008920:0.008920:0.002721:0.010009:0.002721:0.004823:0.009601:0.004248:0.004188
canagliflozin:@0.264225:0.620938:0.352686:0.620938:0.352686:0.605156:0.264225:0.605156:0.009480:0.010024:0.008920:0.010024:0.009873:0.002721:0.002721:0.003515:0.003515:0.009601:0.006123:0.002721:0.009223
 reduced cardio-:@0.352384:0.620938:0.480941:0.620938:0.480941:0.605156:0.352384:0.605156:0.007817:0.004248:0.009525:0.010054:0.008890:0.009480:0.009525:0.010054:0.007817:0.009480:0.010024:0.004248:0.010054:0.002721:0.009601:0.005020
vascular events by 14% and cut the rate of renal decline :@0.076189:0.635312:0.485190:0.635312:0.485190:0.619530:0.076189:0.619530:0.008074:0.010024:0.005564:0.009480:0.008890:0.002721:0.010024:0.004248:0.004717:0.009525:0.008074:0.009525:0.008920:0.004823:0.005564:0.004717:0.010009:0.007801:0.004717:0.008074:0.008074:0.011415:0.004717:0.010024:0.008920:0.010054:0.004717:0.009480:0.008890:0.004823:0.004717:0.004823:0.008920:0.009525:0.004717:0.004248:0.010024:0.004823:0.009525:0.004717:0.009601:0.004445:0.004717:0.004248:0.009525:0.008920:0.010024:0.002721:0.004717:0.010054:0.009525:0.009480:0.002721:0.002721:0.008920:0.009827:0.004188
by 40%, but also doubled the risk for lower-limb amputa-:@0.076189:0.649686:0.480926:0.649686:0.480926:0.633904:0.076189:0.633904:0.010009:0.007801:0.005171:0.008074:0.008074:0.011415:0.003886:0.005171:0.010009:0.008890:0.004823:0.005171:0.010024:0.002721:0.005564:0.009601:0.005171:0.010054:0.009601:0.008890:0.010009:0.002721:0.009525:0.010054:0.005171:0.004823:0.008920:0.009525:0.005171:0.004248:0.002721:0.005564:0.007287:0.005171:0.004445:0.009601:0.004248:0.005171:0.002721:0.009601:0.012262:0.009525:0.004248:0.004717:0.002721:0.002721:0.013879:0.010009:0.005171:0.010024:0.013879:0.010009:0.008890:0.004823:0.010024:0.005020
tion, new Cardiovascular-Outcomes trial data indicate.:@0.076189:0.664060:0.465172:0.664060:0.465172:0.648278:0.076189:0.648278:0.004823:0.002721:0.009601:0.008920:0.003886:0.003886:0.008920:0.009525:0.012262:0.003886:0.011989:0.010024:0.004248:0.010054:0.002721:0.009601:0.008074:0.010024:0.005564:0.009480:0.008890:0.002721:0.010024:0.004248:0.004717:0.012836:0.008890:0.004823:0.009480:0.009601:0.013879:0.009525:0.005564:0.003886:0.004823:0.004248:0.002721:0.010024:0.002721:0.003886:0.010054:0.010024:0.004823:0.010024:0.003886:0.002721:0.008920:0.010054:0.002721:0.009480:0.010024:0.004823:0.009525:0.004188
13:@0.464857:0.658723:0.474398:0.658723:0.474398:0.649570:0.464857:0.649570:0.004683:0.004858
DeCLAre TIMI 58 :@0.076190:0.693272:0.198957:0.693272:0.198957:0.676773:0.076190:0.676773:0.010583:0.007862:0.011793:0.006652:0.011188:0.008769:0.007862:0.004233:0.006350:0.004233:0.013607:0.004233:0.004233:0.008467:0.008467:0.004233
This  trial  evaluated  dapagliflozin  and  cardiovascular :@0.076190:0.710209:0.485100:0.710209:0.485100:0.694426:0.076190:0.694426:0.005836:0.008618:0.002419:0.005261:0.004188:0.010372:0.004521:0.003946:0.002419:0.009722:0.002419:0.004188:0.010387:0.009223:0.007771:0.009722:0.002419:0.008588:0.009722:0.004521:0.009223:0.009752:0.004188:0.010372:0.009752:0.009722:0.009706:0.009722:0.009570:0.002419:0.002419:0.003364:0.003364:0.009298:0.005821:0.002419:0.008618:0.004188:0.010372:0.009722:0.008618:0.009752:0.004188:0.010372:0.009177:0.009722:0.003946:0.009752:0.002419:0.009298:0.007771:0.009722:0.005261:0.009177:0.008588:0.002419:0.009722:0.004551:0.004188
outcomes in type 2 diabetes. In patients with type 2 diabetes :@0.076190:0.724583:0.485115:0.724583:0.485115:0.708800:0.076190:0.708800:0.009298:0.008588:0.004521:0.009177:0.009298:0.013577:0.009223:0.005261:0.003054:0.002419:0.008618:0.003054:0.004521:0.007499:0.009706:0.009223:0.003054:0.007771:0.003054:0.009752:0.002419:0.009722:0.009706:0.009223:0.004521:0.009223:0.005261:0.003583:0.003054:0.002812:0.008618:0.003054:0.009706:0.009722:0.004521:0.002419:0.009223:0.008618:0.004521:0.005261:0.003054:0.011959:0.002419:0.004521:0.008618:0.003054:0.004521:0.007499:0.009706:0.009223:0.003054:0.007771:0.003054:0.009752:0.002419:0.009722:0.009706:0.009223:0.004521:0.009223:0.005866:0.004188
who had or were at risk for atherosclerotic cardiovascular :@0.076190:0.738957:0.485160:0.738957:0.485160:0.723174:0.076190:0.723174:0.011959:0.008618:0.009298:0.005836:0.008618:0.009722:0.009752:0.005836:0.009298:0.003946:0.005836:0.011959:0.009223:0.003946:0.009223:0.005836:0.009722:0.004521:0.005836:0.003946:0.002419:0.005261:0.006985:0.005836:0.004143:0.009298:0.003946:0.005836:0.009722:0.004521:0.008618:0.009223:0.003946:0.009298:0.005261:0.009177:0.002419:0.009223:0.003946:0.009298:0.004521:0.002419:0.009177:0.005836:0.009177:0.009722:0.003946:0.009752:0.002419:0.009298:0.007771:0.009722:0.005261:0.009177:0.008588:0.002419:0.009722:0.004551:0.004188
disease, treatment with dapagliflozin did not result in a higher :@0.076190:0.753331:0.485145:0.753331:0.485145:0.737548:0.076190:0.737548:0.009752:0.002419:0.005261:0.009223:0.009722:0.005261:0.009223:0.003583:0.002963:0.004521:0.003946:0.009223:0.009722:0.004521:0.013577:0.009223:0.008618:0.004521:0.002963:0.011959:0.002419:0.004521:0.008618:0.002963:0.009752:0.009722:0.009706:0.009722:0.009570:0.002419:0.002419:0.003364:0.003364:0.009298:0.005821:0.002419:0.008618:0.002963:0.009752:0.002419:0.009752:0.002963:0.008618:0.009298:0.004521:0.002963:0.003946:0.009223:0.005261:0.008588:0.002419:0.004521:0.002963:0.002419:0.008618:0.002963:0.009722:0.002963:0.008618:0.002419:0.009570:0.008618:0.009223:0.004551:0.004188
or lower rate of MACE than placebo, but did result in a lower :@0.076190:0.767705:0.485145:0.767705:0.485145:0.751923:0.076190:0.751923:0.009298:0.003946:0.003296:0.002419:0.009298:0.011959:0.009223:0.003946:0.003296:0.003946:0.009722:0.004521:0.009223:0.003296:0.009298:0.004143:0.003296:0.013290:0.010583:0.011687:0.007499:0.003296:0.004521:0.008618:0.009722:0.008618:0.003296:0.009706:0.002419:0.009722:0.009177:0.009223:0.009706:0.009298:0.003583:0.003296:0.009706:0.008588:0.004521:0.003296:0.009752:0.002419:0.009752:0.003296:0.003946:0.009223:0.005261:0.008588:0.002419:0.004521:0.003296:0.002419:0.008618:0.003296:0.009722:0.003296:0.002419:0.009298:0.011959:0.009223:0.004551:0.004188
rate of cardiovascular death (4.9% :@0.076190:0.782079:0.326108:0.782079:0.326108:0.766297:0.076190:0.766297:0.003946:0.009722:0.004521:0.009223:0.006728:0.009298:0.004143:0.006728:0.009177:0.009722:0.003946:0.009752:0.002419:0.009298:0.007771:0.009722:0.005261:0.009177:0.008588:0.002419:0.009722:0.003946:0.006728:0.009752:0.009223:0.009722:0.004521:0.008618:0.006728:0.004974:0.007771:0.003583:0.007771:0.011112:0.004188
vs.:@0.328648:0.782079:0.345869:0.782079:0.345869:0.766297:0.328648:0.766297:0.007771:0.005261:0.004188
 5.8%; hazard ratio, :@0.345264:0.782079:0.485130:0.782079:0.485130:0.766297:0.345264:0.766297:0.006728:0.007771:0.003583:0.007771:0.011112:0.003583:0.006728:0.008618:0.009722:0.005821:0.009722:0.003946:0.009752:0.006728:0.003946:0.009722:0.004521:0.002419:0.009298:0.004188:0.004188
0.83; 95% CI, 0.73 to 0.95; p=0.005) or hospitalisation for heart :@0.076190:0.796453:0.485191:0.796453:0.485191:0.780671:0.076190:0.780671:0.007771:0.003583:0.007771:0.007771:0.003583:0.004037:0.007771:0.007771:0.011112:0.004037:0.011687:0.002812:0.003583:0.004037:0.007771:0.003583:0.007771:0.007771:0.004037:0.004521:0.009298:0.004037:0.007771:0.003583:0.007771:0.007771:0.003583:0.004037:0.008346:0.008557:0.007771:0.003583:0.007771:0.007771:0.007771:0.004974:0.004037:0.009298:0.003946:0.004037:0.008618:0.009298:0.005261:0.009706:0.002419:0.004521:0.009722:0.002419:0.002419:0.005261:0.009722:0.004521:0.002419:0.009298:0.008618:0.004037:0.004143:0.009298:0.003946:0.004037:0.008618:0.009223:0.009722:0.003946:0.005125:0.004188
failure (hazard ratio, 0.73; 95% CI, 0.61 to 0.88), a finding that :@0.076190:0.810827:0.485115:0.810827:0.485115:0.795045:0.076190:0.795045:0.004143:0.009722:0.002419:0.002419:0.008588:0.003946:0.009223:0.003946:0.004974:0.008618:0.009722:0.005821:0.009722:0.003946:0.009752:0.003946:0.003946:0.009722:0.004521:0.002419:0.009298:0.003583:0.003946:0.007771:0.003583:0.007771:0.007771:0.003583:0.003946:0.007771:0.007771:0.011112:0.003946:0.011687:0.002812:0.003583:0.003946:0.007771:0.003583:0.007771:0.007771:0.003946:0.004521:0.009298:0.003946:0.007771:0.003583:0.007771:0.007771:0.004974:0.003583:0.003946:0.009722:0.003946:0.003379:0.003379:0.008618:0.009752:0.002419:0.008618:0.009570:0.003946:0.004521:0.008618:0.009722:0.005125:0.004188
reflects a lower rate of hospitalisation for heart failure.:@0.076190:0.825202:0.432637:0.825202:0.432637:0.809419:0.076190:0.809419:0.003946:0.009223:0.003364:0.003364:0.009223:0.009177:0.004521:0.005261:0.003583:0.009722:0.003583:0.002419:0.009298:0.011959:0.009223:0.003946:0.003583:0.003946:0.009722:0.004521:0.009223:0.003583:0.009298:0.004143:0.003583:0.008618:0.009298:0.005261:0.009706:0.002419:0.004521:0.009722:0.002419:0.002419:0.005261:0.009722:0.004521:0.002419:0.009298:0.008618:0.003583:0.004143:0.009298:0.003946:0.003583:0.008618:0.009223:0.009722:0.003946:0.004521:0.003583:0.004143:0.009722:0.002419:0.002419:0.008588:0.003946:0.009223:0.004188
14:@0.431987:0.819856:0.441353:0.819856:0.441353:0.810702:0.431987:0.810702:0.004507:0.004858
 :@0.441356:0.825155:0.445544:0.825155:0.445544:0.809372:0.441356:0.809372:0.004188
GluCAGOn-liKe PePtiDe-1 reCePtOr AGOnists :@0.076190:0.857758:0.480877:0.857758:0.480877:0.837593:0.076190:0.837593:0.014783:0.007392:0.011087:0.013674:0.012935:0.014783:0.014783:0.012935:0.007022:0.007392:0.004435:0.010718:0.008870:0.004435:0.009609:0.008870:0.009609:0.007022:0.004435:0.012196:0.008870:0.007022:0.009609:0.004435:0.009979:0.008870:0.013674:0.008870:0.009609:0.007022:0.014783:0.009979:0.004435:0.012935:0.014783:0.014783:0.012935:0.004435:0.008870:0.007022:0.009609:0.005174
Table 4 lists the glucagon-like peptide-1 receptor ago-:@0.076190:0.873904:0.480957:0.873904:0.480957:0.858122:0.076190:0.858122:0.006441:0.010326:0.010311:0.003024:0.009827:0.005382:0.008376:0.005382:0.003024:0.003024:0.005866:0.005125:0.005866:0.005382:0.005125:0.009223:0.009827:0.005367:0.010175:0.003024:0.009192:0.009782:0.010326:0.010175:0.009903:0.009223:0.005020:0.003024:0.003024:0.007590:0.009827:0.005367:0.010311:0.009827:0.010311:0.005125:0.003024:0.010357:0.009827:0.005020:0.008376:0.005382:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.005352:0.010326:0.010175:0.009903:0.005020
nists (GLp1-1RA) studies that have been conducted. :@0.076190:0.888278:0.485160:0.888278:0.485160:0.872496:0.076190:0.872496:0.009223:0.003024:0.005866:0.005125:0.005866:0.008240:0.005579:0.013184:0.006985:0.008950:0.008376:0.005020:0.008376:0.009177:0.011188:0.005579:0.008331:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.008240:0.005125:0.009223:0.010326:0.005125:0.008240:0.009223:0.010326:0.008376:0.009827:0.008240:0.010311:0.009827:0.009827:0.009223:0.008240:0.009782:0.009903:0.009223:0.010357:0.009192:0.009782:0.005125:0.009827:0.010357:0.004188:0.004188
 :@0.195948:0.888278:0.200182:0.888278:0.200182:0.871780:0.195948:0.871780:0.004233
Only those  of  relevance  to  the  current  article  will be :@0.076190:0.902653:0.485130:0.902653:0.485130:0.886870:0.076190:0.886870:0.013138:0.009223:0.003024:0.008104:0.007015:0.005125:0.009223:0.009903:0.005866:0.009827:0.004188:0.002812:0.009903:0.004747:0.004188:0.002812:0.004551:0.009827:0.003024:0.009827:0.008376:0.010326:0.009223:0.009782:0.009827:0.004188:0.002812:0.005125:0.009903:0.004188:0.002812:0.005125:0.009223:0.009827:0.004188:0.002812:0.009782:0.009192:0.004551:0.004551:0.009827:0.009223:0.005125:0.004188:0.002797:0.010326:0.004551:0.005125:0.003024:0.009782:0.003024:0.009827:0.004188:0.002812:0.012564:0.003024:0.003024:0.003024:0.007015:0.010311:0.009827:0.004188
discussed. semaglutide studies have been conducted :@0.076190:0.916888:0.485145:0.916888:0.485145:0.901105:0.076190:0.901105:0.010357:0.003024:0.005866:0.009782:0.009192:0.005866:0.005866:0.009827:0.010357:0.004188:0.005624:0.007529:0.009827:0.014182:0.010326:0.010175:0.003024:0.009192:0.005125:0.003024:0.010357:0.009827:0.005624:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.005624:0.009223:0.010326:0.008376:0.009827:0.005624:0.010311:0.009827:0.009827:0.009223:0.005609:0.009782:0.009903:0.009223:0.010357:0.009192:0.009782:0.005125:0.009827:0.010357:0.004188
in south Africa (sA), but this drug has not yet been regis-:@0.076190:0.931124:0.480957:0.931124:0.480957:0.915341:0.076190:0.915341:0.003024:0.009223:0.003765:0.007529:0.009903:0.009192:0.005125:0.009223:0.003750:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.003750:0.005579:0.007529:0.011188:0.005579:0.004188:0.003765:0.010311:0.009192:0.005125:0.003765:0.005125:0.009223:0.003024:0.005866:0.003765:0.010357:0.004551:0.009192:0.010175:0.003750:0.009223:0.010326:0.005866:0.003765:0.009223:0.009903:0.005125:0.003750:0.008104:0.009827:0.005125:0.003765:0.010311:0.009827:0.009827:0.009223:0.003765:0.004551:0.009827:0.010175:0.003024:0.005866:0.005020
tered for use. Lixisenatide is not registered in sA. :@0.076190:0.945359:0.427133:0.945359:0.427133:0.929576:0.076190:0.929576:0.005125:0.009827:0.004551:0.009827:0.010357:0.004188:0.004747:0.009903:0.004551:0.004188:0.009192:0.005866:0.009827:0.004188:0.004188:0.006985:0.003024:0.007257:0.003024:0.005866:0.009827:0.009223:0.010326:0.005125:0.003024:0.010357:0.009827:0.004188:0.003024:0.005866:0.004188:0.009223:0.009903:0.005125:0.004188:0.004551:0.009827:0.010175:0.003024:0.005866:0.005125:0.009827:0.004551:0.009827:0.010357:0.004188:0.003024:0.009223:0.004188:0.007529:0.011188:0.004188:0.004188
Meier JJ. Nat Rev Endocrinol.2012;8:728-742.:@0.532658:0.566765:0.670470:0.566765:0.670470:0.560449:0.532658:0.560449:0.005597:0.003736:0.001492:0.003736:0.002238:0.001868:0.003360:0.003360:0.001868:0.001868:0.004852:0.003736:0.001868:0.001868:0.004852:0.003736:0.003360:0.001868:0.004482:0.003736:0.003736:0.003736:0.003360:0.002238:0.001492:0.003736:0.003736:0.001492:0.001868:0.003736:0.003736:0.003736:0.003736:0.001868:0.003736:0.001868:0.003736:0.003736:0.003736:0.002238:0.003736:0.003736:0.003736:0.001868
figure 4. emPA-reG and CV death:@0.076190:0.242628:0.325957:0.242628:0.325957:0.226130:0.076190:0.226130:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.004233:0.008467:0.004233:0.004233:0.007862:0.013607:0.008467:0.011188:0.006350:0.008769:0.007862:0.012700:0.004233:0.009979:0.009071:0.009979:0.004233:0.011793:0.010583:0.004233:0.009979:0.009676:0.009979:0.004536:0.009071
 :@0.325942:0.242628:0.330175:0.242628:0.330175:0.226130:0.325942:0.226130:0.004233
Zinman B, :@0.076190:0.209533:0.117566:0.209533:0.117566:0.200765:0.076190:0.200765:0.004032:0.001680:0.005124:0.007879:0.005737:0.005124:0.002327:0.004821:0.002327:0.002327
et al:@0.117566:0.209533:0.135617:0.209533:0.135617:0.200765:0.117566:0.200765:0.005460:0.002847:0.002327:0.005737:0.001680
. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. :@0.135617:0.209533:0.440492:0.209533:0.440492:0.200765:0.135617:0.200765:0.002327:0.002327:0.004502:0.007879:0.005728:0.005737:0.005653:0.001680:0.001680:0.002037:0.002037:0.005502:0.003570:0.001680:0.005124:0.002327:0.002327:0.005434:0.005737:0.002528:0.005754:0.001680:0.005502:0.004653:0.005737:0.003259:0.005434:0.005107:0.001680:0.005737:0.002528:0.002327:0.005502:0.005107:0.002847:0.005434:0.005502:0.007879:0.005460:0.003259:0.002327:0.002327:0.005737:0.005124:0.005754:0.002327:0.007879:0.005502:0.002528:0.002847:0.005737:0.001680:0.001680:0.002847:0.004502:0.002327:0.001680:0.005124:0.002327:0.002847:0.004502:0.005728:0.005460:0.002327:0.004653:0.002327:0.005754:0.001680:0.005737:0.005728:0.005460:0.002847:0.005460:0.003259:0.002327:0.002327
N Engl J Med.:@0.076190:0.217230:0.131652:0.217230:0.131652:0.208462:0.076190:0.208462:0.006216:0.002327:0.004502:0.005124:0.005653:0.001680:0.002327:0.004049:0.002327:0.007719:0.005460:0.005754:0.002327
 2015:@0.131644:0.217230:0.152584:0.217230:0.152584:0.208462:0.131644:0.208462:0.002327:0.004653:0.004653:0.004653:0.004653
figure 5. emPA-reG outcome and hospitalisation for :@0.076190:0.423089:0.458400:0.423089:0.458400:0.406590:0.076190:0.406590:0.007257:0.003629:0.009979:0.009071:0.004838:0.009676:0.004233:0.008467:0.004233:0.004233:0.007862:0.013607:0.008467:0.011188:0.006350:0.008769:0.007862:0.012700:0.004233:0.009676:0.009071:0.004536:0.009676:0.009676:0.014212:0.009676:0.004233:0.009979:0.009071:0.009979:0.004233:0.009071:0.009676:0.006652:0.009979:0.003629:0.004536:0.009979:0.003629:0.003629:0.006652:0.009979:0.004536:0.003629:0.009676:0.009071:0.004233:0.004233:0.009676:0.004838:0.004233
heart failure:@0.076190:0.436170:0.163578:0.436170:0.163578:0.419671:0.076190:0.419671:0.009071:0.009676:0.009979:0.004838:0.004536:0.004233:0.004233:0.009979:0.003629:0.003629:0.009071:0.004838:0.009676
Zinman B, :@0.076190:0.397150:0.117566:0.397150:0.117566:0.388382:0.076190:0.388382:0.004032:0.001680:0.005124:0.007879:0.005737:0.005124:0.002327:0.004821:0.002327:0.002327
et al:@0.117566:0.397150:0.135617:0.397150:0.135617:0.388382:0.117566:0.388382:0.005460:0.002847:0.002327:0.005737:0.001680
. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.:@0.135617:0.397150:0.438165:0.397150:0.438165:0.388382:0.135617:0.388382:0.002327:0.002327:0.004502:0.007879:0.005728:0.005737:0.005653:0.001680:0.001680:0.002037:0.002037:0.005502:0.003570:0.001680:0.005124:0.002327:0.002327:0.005434:0.005737:0.002528:0.005754:0.001680:0.005502:0.004653:0.005737:0.003259:0.005434:0.005107:0.001680:0.005737:0.002528:0.002327:0.005502:0.005107:0.002847:0.005434:0.005502:0.007879:0.005460:0.003259:0.002327:0.002327:0.005737:0.005124:0.005754:0.002327:0.007879:0.005502:0.002528:0.002847:0.005737:0.001680:0.001680:0.002847:0.004502:0.002327:0.001680:0.005124:0.002327:0.002847:0.004502:0.005728:0.005460:0.002327:0.004653:0.002327:0.005754:0.001680:0.005737:0.005728:0.005460:0.002847:0.005460:0.003259:0.002327
N Engl J Med.:@0.076190:0.404847:0.131652:0.404847:0.131652:0.396079:0.076190:0.396079:0.006216:0.002327:0.004502:0.005124:0.005653:0.001680:0.002327:0.004049:0.002327:0.007719:0.005460:0.005754:0.002327
 2015:@0.131644:0.404847:0.152584:0.404847:0.152584:0.396079:0.131644:0.396079:0.002327:0.004653:0.004653:0.004653:0.004653